<mods:mods version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" xmlns:mods="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><mods:titleInfo><mods:title>SAFETY AND EFFICACY OF LONG-TERM TREATMENT WITH NUCLEOS(T)IDE ANALOGUES IN CHRONIC HEPATITIS B</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Bakhtiyarova Dilnura</mods:namePart><mods:namePart type="family">Akbarovna</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Chronic hepatitis B (CHB) remains a major global public health problem, leading to progressive liver disease, cirrhosis, and hepatocellular carcinoma. Long-term antiviral therapy with nucleos(t)ide analogues (NAs) is the cornerstone of CHB management, aiming to suppress hepatitis B virus (HBV) replication, prevent disease progression, and reduce liver-related complications. Despite proven antiviral efficacy, prolonged NA therapy raises concerns regarding drug resistance, safety, renal and bone toxicity, and long-term patient adherence.
This study was conducted at the Khorezm Regional Multidisciplinary Medical Center and aimed to evaluate the safety and efficacy of long-term treatment with nucleos(t)ide analogues in patients with chronic hepatitis B. Patients were assessed based on virological, biochemical, and clinical parameters during extended antiviral therapy. The results demonstrate that long-term NA treatment effectively suppresses HBV replication, improves liver function, and is generally well tolerated, confirming the importance of continuous antiviral therapy in the management of chronic hepatitis B.</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2026-01-22</mods:dateIssued></mods:originInfo><mods:originInfo><mods:publisher>Center for Tech and Media Research</mods:publisher></mods:originInfo><mods:genre>Maqola</mods:genre></mods:mods>